| Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim |
RISE-CD, NCT06589895: Correlation Between RISANKIZUMAB's Trough Levels, Clinical and Biological Remission in Moderate to Severe Crohn's Disease: a Retrospective Multicentric Study |
|
|
| Completed | N/A | 40 | Europe | | Centre Hospitalier Universitaire de Nīmes | Inflammatory Bowel Diseases | 05/24 | 05/24 | | |
NCT04799990: Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting |
|
|
| Withdrawn | N/A | 0 | NA | Risankizumab, Skyrizi, Comparator 1, Comparator 2 | AbbVie | Psoriasis | 03/22 | 03/22 | | |
| No Longer Available | N/A | | NA | Risankizumab, ABBV-066, BI 655066 | AbbVie | Crohn's Disease, Ulcerative Colitis (UC) | | | | |
COMMODUS, NCT06126146: An Observational Study to Assess Participant-Reported Real-World Experience of Risankizumab On-body Injector (OBI) for the Treatment of Crohn's Disease in Adult Participants in the United Kingdom (UK) |
|
|
| Completed | N/A | 53 | Europe | | AbbVie | Crohn's Disease | 05/24 | 05/24 | | |
VOICE, NCT06249555: -Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study |
|
|
| Recruiting | N/A | 300 | Canada, US | Vedolizumab (VDZ), Entyvio, Ustekinumab (UST), Stelara, Risankizumab (RISA), Skyrizi, Guselkumab (GUS), Tremfya, Mirikizumab (MIR), Omvoh | Alimentiv Inc., Takeda | Crohn's Disease | 06/26 | 12/26 | | |
REDEFINE, NCT06247319: Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in Greece |
|
|
| Recruiting | N/A | 250 | Europe | | AbbVie | Moderate Plaque Psoriasis, Moderate Psoriasis, Psoriasis | 10/27 | 10/27 | | |
prIMMa, NCT04780516: Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of Care |
|
|
| Active, not recruiting | N/A | 141 | RoW | | AbbVie | Psoriasis | 01/24 | 12/26 | | |
NCT06298188: Risankizumab in Children With Crohn's Disease (RisaKids) |
|
|
| Recruiting | N/A | 90 | RoW | Risankizumab | Shaare Zedek Medical Center | Crohn Disease | 10/26 | 10/26 | | |
NCT04818385: Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan |
|
|
| Completed | N/A | 240 | RoW | | AbbVie | Psoriasis | 08/25 | 08/25 | | |
PERIS, NCT06764693: An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis |
|
|
| Recruiting | N/A | 1200 | Europe, RoW | | AbbVie | Psoriatic Arthritis | 02/29 | 02/29 | | |
SUNRISE-UC, NCT06764706: Study to Assess Change in Disease Activity of Risankizumab Treatment in Adult Participants With Moderate to Severe Ulcerative Colitis |
|
|
| Recruiting | N/A | 200 | Europe | | AbbVie | Ulcerative Colitis | 07/28 | 07/28 | | |
NCT04433442: Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic Arthritis |
|
|
| Active, not recruiting | N/A | 2324 | RoW | | AbbVie | Psoriasis, Psoriatic Arthritis | 06/25 | 06/25 | | |
SKYNETICS, NCT07308067: Kinetics of Transmural Healing in Patients With Crohns Disease Treated With Risankizumab (SKYRIZI®) |
|
|
| Recruiting | N/A | 100 | Europe | | University Hospital, Clermont-Ferrand | Crohn Disease (CD), Transmural Response | 03/26 | 07/26 | | |
NCT07166315: Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor |
|
|
| Recruiting | N/A | 700 | Europe | observational study | Adelphi Real World | Axial Spondylarthritis (axSpA), Psoriatic Arthritis (PsA) | 03/27 | 03/27 | | |
CROHNOS, NCT07073079: A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting |
|
|
| Recruiting | N/A | 250 | Europe | | AbbVie | Crohn's Disease | 12/27 | 12/27 | | |
VALUE, NCT03982394: Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis |
|
|
| Completed | N/A | 2759 | Europe, Canada, Japan, RoW | | AbbVie | Chronic Plaque Psoriasis | 09/25 | 09/25 | | |
DREAM, NCT07039110: Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis |
|
|
| Recruiting | N/A | 700 | Europe, Canada, Japan, RoW | | AbbVie | Plaque Psoriasis | 03/28 | 03/28 | | |
RISE UP, NCT07136116: Study to Assess Change in Disease Activity of Risankizumab Treatment in Japanese Participants With Moderate to Severe Ulcerative Colitis |
|
|
| Recruiting | N/A | 200 | Japan | | AbbVie | Ulcerative Colitis | 02/30 | 02/30 | | |
EFFECT-1LAT, NCT07177209: Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population |
|
|
| Not yet recruiting | N/A | 4000 | Europe | Non-Interventional Study, etrasimod, ozanimod, upadicitinib, filgotinib, tofacitinib, vedolizumab, guselkumab, ustekinumab, risankizumab, adalimumab, infliximab, golimumab | Pfizer | Ulcerative Colitis | 03/26 | 03/26 | | |
APPRISE, NCT05841537: An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD) |
|
|
| Active, not recruiting | N/A | 1034 | Europe, Canada, Japan, RoW | | AbbVie | Crohn's Disease | 07/28 | 07/28 | | |
NCT04846959: Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications |
|
|
| Recruiting | N/A | 818 | US | Risankizumab, Skyrizi, Comparator | AbbVie, PPD Development, LP | Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment | 06/32 | 06/32 | | |
